CN105641081A - 一种治疗母猪子宫内膜炎的中药口服液 - Google Patents
一种治疗母猪子宫内膜炎的中药口服液 Download PDFInfo
- Publication number
- CN105641081A CN105641081A CN201610030763.XA CN201610030763A CN105641081A CN 105641081 A CN105641081 A CN 105641081A CN 201610030763 A CN201610030763 A CN 201610030763A CN 105641081 A CN105641081 A CN 105641081A
- Authority
- CN
- China
- Prior art keywords
- oral liquid
- weight
- herba leonuri
- hours
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 63
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 208000004145 Endometritis Diseases 0.000 title abstract description 19
- RLQYRXCUPVKSAW-UHFFFAOYSA-M 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium;chloride Chemical compound [Cl-].COC1=C(OC)C=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=C1 RLQYRXCUPVKSAW-UHFFFAOYSA-M 0.000 claims abstract description 32
- RIDQRIPSFYHEGL-UHFFFAOYSA-N fibrauretin Natural products CC12CC=C3C(=O)OC(CC3(C)C1C(=O)C=CC2=O)c4cocc4 RIDQRIPSFYHEGL-UHFFFAOYSA-N 0.000 claims abstract description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 65
- 210000004291 uterus Anatomy 0.000 claims description 32
- 239000000284 extract Substances 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 17
- 238000001914 filtration Methods 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 12
- 239000012467 final product Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 8
- 238000009835 boiling Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000001953 recrystallisation Methods 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 8
- 235000010234 sodium benzoate Nutrition 0.000 claims description 8
- 239000004299 sodium benzoate Substances 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 4
- 238000007605 air drying Methods 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 238000002386 leaching Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 238000002525 ultrasonication Methods 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 33
- 150000001875 compounds Chemical class 0.000 description 27
- 238000012360 testing method Methods 0.000 description 13
- 230000000694 effects Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010046793 Uterine inflammation Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000005498 polishing Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010061926 Purulence Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 240000004859 Gamochaeta purpurea Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 206010053636 Obstetric infection Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000002815 broth microdilution Methods 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗母猪子宫内膜炎的中药口服液。1000mL所述治疗母猪子宫内膜炎的中药口服液中含有如下重量的生药:黄藤素300—400g,连翘100—300g,赤芍100—300g,益母草150—250g。本发明治疗母猪子宫内膜炎的中药口服液稳定性好,抗菌效果明显增强。
Description
技术领域
本发明涉及中兽药制剂领域,具体涉及一种治疗猪子宫内膜炎的复方黄藤素口服液。
背景技术
母猪产后子宫内膜炎是病原微生物侵入子宫,突破了生殖器官的防御机能而引起的一种常见病,尤以规模化猪场和引入的纯种母猪易发,如果处理不当,对生产危害极大。据统计,发情不正常或延迟发情、屡配不孕的母猪85%以上是由于患子宫内膜炎,特别是炎热夏季是其高发季节,更需引起养猪场(户)的高度重视。
目前,使用的中药剂型有散剂、注射剂等。散剂一般采用拌料和饮水方式服药,由于药物生物利用度低,很多药物很难达到应有的药效,还有适口性问题会导致动物饮食下降。注射液一般每天需要用药2次,操作比较麻烦,同时给动物造成的应激也是注射剂使用受限的一个方面。
发明内容
本发明旨在克服现有技术的不足,提供一种治疗母猪子宫内膜炎的中药口服液。
为了达到上述目的,本发明提供的技术方案为:
1000mL所述治疗母猪子宫内膜炎的中药口服液由如下重量的生药制得:黄藤素300—400g,连翘100—300g,赤芍100—300g,益母草150—250g。
优选地,1000mL所述中药口服液由如下重量的生药制得:黄藤素300—400g,连翘200—300g,赤芍200—300g,益母草200g。
优选地,1000mL所述中药口服液中还含有如下组分:乙醇80—120mL,蔗糖80—120g,苯甲酸钠1.5—2.5g。
优选地,1000mL所述中药口服液中还含有如下组分:体积百分比含量为95%的乙醇100mL,蔗糖100g,苯甲酸钠2g。
下面对本发明作进一步说明:
本发明是一种由天然药材的活性成份构成的用于治疗猪子宫内膜炎的口服液。
本发明所述治疗母猪子宫内膜炎的中药口服液的制备步骤如下:
按所述比例准备生药和组分
1、中草药黄藤素的提取
提取黄藤素:取黄藤素饮片粉碎备用,取黄藤素干粉按料剂比为1:(4—6)加入体积百分比浓度为1.5—2.5%的H2SO4浸润8—12分钟,然后超声作用,25—35分钟,纱布过滤,然后用高速离心机进行离心得上清液,上清液调PH值到7.0后按每100mL上清液加入6—8gNaCl,搅拌使NaCl充分溶解,静置20—28小时后再离心,得沉淀即为粗碱,粗碱自然风干粉碎,然后再进行重结晶及可得到黄藤素提取物;所述重结晶过程是用体积百分比浓度为80%的酒精提取2—3次,提取液用HCl调PH值到7.0,冷却结晶;本提取方法为优化方案,较常规煎煮法和醇提法其黄藤素含量提高20.8%和7.9%。
2、中草药连翘的提取
提取连翘:取连翘,粉碎成粗粉,加水煎煮2—3次,每次加水重量均为连翘粗粉重量的6—8倍,每次1—1.5小时,合并煎液,滤过,滤液于60℃以下减压浓缩至相对密度为1.1—1.2的浸膏,放冷,加入3—5倍量乙醇,搅匀,静置1.5—2.5小时,沉淀,滤过,滤液减压回收乙醇,浓缩液喷雾干燥,即得。
3、中草药益母草的提取
提取益母草:将益母草加水煎煮3次,加水重量分别为益母草重量的13—17倍1.5—2小时,10—12倍量1—1.5小时,9—10倍量0.5—1小时,滤过,合并滤液,浓缩,冷却,得益母草提取浓缩液体积,加入与益母草提取浓缩液体积等量的体积百分比浓度为95%的乙醇,搅匀,常温静置20—28小时,滤过,滤渣用体积百分比浓度为45%的乙醇洗涤,合并滤液与洗液,减压浓缩,浓缩液即得;所述倍量是加水重量与益母草重量的比值。
4、中草药赤芍的提取
提取赤芍:将赤芍加入7—9倍量体积百分比浓度为70﹪的乙醇,提取2—3次,每次浸取1—1.5小时,过滤,收集滤液,减压浓缩并回收乙醇,浓缩液即得;所述倍量是加水重量与赤芍重量的比值。
5、将黄藤素、连翘、赤芍、益母草中草材的提取物混合、加入乙醇(体积百分比浓度为95%)及注射用水溶解后加入蔗糖、苯甲酸钠,过滤、灌封、灭菌。
本发明的药材中:黄藤素具有清热解毒,对子宫内膜炎,霉毒性阴道炎,产褥期感染具有很好的疗效。连翘具有清热,解毒,散结,消肿的功效,有助于消除患病母畜子宫炎症和肿胀。赤芍具有显著的抗炎作用,对多种致炎剂所致的毛细血管通透性亢进、渗出和水肿以及免疫性炎症均有显著的抑制作用。益母草能兴奋子宫,促进子宫收缩,有助于子宫内脓液的排出,促进患病母畜子宫机能恢复,利于母畜早日怀孕。另外,口服液主要采用饮水方式给药,使用方便。
具体实施方式
实施例1
所述治疗母猪子宫内膜炎的中药口服液由如下重量的生药及组分制得:
注射用水补齐容量至1000ml。
制备方法如下:
(1)按所述比例准备生药和组分;
(2)提取黄藤素:取黄藤素饮片粉碎备用,取黄藤素干粉按料剂比为1:5加入体积百分比浓度为2%的H2SO4浸润10分钟,然后超声作用,30分钟,4层纱布过滤,然后用高速离心机进行离心得上清液,上清液调PH值到7.0后按每100mL上清液加入7gNaCl,搅拌使NaCl充分溶解,搅拌使NaCl充分溶解,静置24小时后再离心,得沉淀即为粗碱,粗碱自然风干粉碎,然后再进行重结晶及可得到黄藤素提取物;所述重结晶过程是用体积百分比浓度为80%的酒精提取3次,提取液用HCl调PH值到7.0,冷却结晶;
(3)提取连翘:取连翘,粉碎成粗粉,加水煎煮3次,每次加水重量均为连翘粗粉重量的7倍,每次1.5小时,合并煎液,滤过,滤液于60℃以下减压浓缩至相对密度为1.1—1.2的浸膏,放冷,加入4倍量乙醇,搅匀,静置2小时,沉淀,滤过,滤液减压回收乙醇,浓缩液喷雾干燥,即得;
(4)提取益母草:将益母草加水煎煮3次,分别为15倍量2小时,12倍量1.5小时,10倍量1小时,滤过,合并滤液,浓缩,冷却,得益母草提取浓缩液体积,加入与益母草提取浓缩液体积等量的体积百分比浓度为95%的乙醇,搅匀,常温静置24小时,滤过,滤渣用体积百分比浓度为45%的乙醇洗涤,合并滤液与洗液,减压浓缩,浓缩液即得;所述倍量是加水重量与益母草重量的比值;
(5)提取赤芍:将赤芍加入8倍量体积百分比浓度为70﹪的乙醇,提取3次,每次浸取1小时,过滤,收集滤液,减压浓缩并回收乙醇,浓缩液即得;所述倍量是加水重量与赤芍重量的比值;
(6)将黄藤素、连翘、赤芍、益母草中草材的提取物混合、加入乙醇及水溶解后加入蔗糖、苯甲酸钠,过滤、灌封、灭菌。
实施例2
所述治疗母猪子宫内膜炎的中药口服液由如下重量的生药及组分制得:
注射用水补齐容量至1000ml。
制备方法同实施例1。
实施例3
所述治疗母猪子宫内膜炎的中药口服液由如下重量的生药及组分制得:
注射用水补齐容量至1000ml。
制备方法同实施例1。
实施例4
实施例1至3任一项治疗母猪子宫内膜炎的中药口服液(以下简称“复方黄藤素口服液”)对子宫内膜炎病原菌的体外抑菌试验
1材料与方法
1.1药物
复方黄藤素口服液。
1.2培养基
普通肉汤培养基、普通琼脂平皿培养基、鲜血琼脂平皿培养基。
1.3菌种
从湖南省某猪场分离的五种病原菌:大肠杆菌、金黄色葡萄球菌、化脓链球菌、普通变形杆菌和克雷伯氏杆菌。
1.4试验方法
1.4.1菌液的制备
将从患有子宫内膜炎的母猪分泌物中分离到的五种病原菌,接种于普通营养肉汤培养基,在37℃的恒温箱中培养18~24h,用麦氏比浊法,经肉汤稀释,使其在625nm处吸光度为0.8。
1.4.2纸片的制备
用直径5.5mm的打孔器在新华一号定性滤纸上打孔,得滤纸片,将30片滤纸装于一青霉素小瓶中,在121℃条件下高压蒸汽灭菌20min,后往每一小瓶中加药液1ml,使其充分浸透5min,在超净工作台上无菌条件下吹干,保存于4℃冰箱中备用。
1.4.3体外抑菌试验
运用药敏纸片抑菌法
2结果
2.1抑菌结果
采用药敏纸片法测定复方黄藤素口服液对母猪临床型的五种病原菌的抑菌效果。不同的细菌用各自合适的培养基培养,置37℃恒温箱中培养24h,每种菌做5张药敏纸片,量取每张纸片的抑菌圈直径,取其均值得结果如表1:
表1复方黄藤素口服液对五种病原菌的抑菌圈直径(单位:mm)
注:直径小于8mm为低敏;8-15mm为中敏;15mm以上为高敏;—表示无抑菌圈
由表1可知,复方黄藤素口服液对五种病原菌都呈现较强的抑制作用。
实施例5
复方黄藤素口服液性能测定
1、材料与方法
1.1材料
复方黄藤素口服液。
1.2.方法
1.2.1含量测定
精密移取本品适量,采取高效液相色谱法测定其盐酸巴马汀的含量。
1.2.2热稳定性试验
精密移取复方黄藤素口服液10ml,放入棕色磨口瓶中,分别在40℃、60℃的条件下放置1w,分别在第1d、3d、7d采取高效液相色谱法测定其盐酸巴马汀的含量,并观察复方黄藤素口服液的色泽变化。
1.2.3光照试验
精密移取复方黄藤素口服液10ml,分别放入棕色瓶和普通玻璃瓶中,将它们暴露放置在2000LX照度光下(相当于一般室内照度)照射,分别在不同时间,按“上述方法测定含量。
2.结果
2.1性状
本品为黄色澄明液体。
2.2含量测定
共检验3批复方黄藤素口服液的盐酸巴马汀平均含量为2.05%。RSD为0.71%。
2.3热稳定性试验
实验结果表明:随着放置时间的延长,其外观性状与刚放置时差异不大,但含量略有下降,并且在高温条件下,含量下降不明显(P<0.01)。结果见表2。
表2复方黄藤素口服液热稳定性实验结果
2.4光稳定性试验结果:实验结果表明:随着放置时间的延长,在2000LX照度条件下,含量自然放置要比避光放置下降的明显(P<O.01),说明本制剂应避光保存。结果见表3。
表3光稳定性试验结果
注:避光组与自然放置组比较,*P<0.05,**P<0.01。
实施例6
复方黄藤素口服液临床治疗试验
母猪子宫内膜炎疾病的治疗方法有很多,有全身性疗法、子宫内疗法等。本试验采用复方中药口服液对比其他组方提取液对患猪进行子宫口服治疗,取得了很好的疗效。
1材料与方法
1.1材料
复方黄藤素口服液、连翘+益母草提取液,赤芍+益母草提取液,黄藤+益母草提取
液,黄藤+连翘+益母草提取液,黄藤+赤芍+益母草提取液。
1.2实验动物
湖南四个母猪场临床确诊的患子宫内膜炎母猪230头。
1.3方法
1.3.1将黄藤素口服液药、连翘+益母草提取液,赤芍+益母草提取液,黄藤+益母草提取液,黄藤+连翘+益母草提取液,黄藤+赤芍+益母草提取液分别添加至饮水中(适量添加蔗糖、糖精钠),每头猪每次10ml,每天一次
1.3.2观察患母猪的临床表现,对患猪及时进行阴道检查。
判定标准治愈:临床症状消失,子宫机能恢复正常,发情及发情时粘液正常,可以进行人工受精。好转:临床症状消失,子宫机能基本恢复正常,但发情时粘液还不正常,仍不能进行人工受精。无效:临床症状及子宫机能均未见好转。
2结果与分析
2.1复方黄藤素口服液治疗母猪子宫内膜炎对比试验(见表4)
复方黄藤素口服液对母猪子宫内膜炎的治愈效果明显高于连翘+益母草提取液,赤芍+益母草提取液,黄藤+益母草提取液,黄藤+连翘+益母草提取液,黄藤+赤芍+益母草提取液组。差异显著。
表4复方黄藤素口服液治疗母猪子宫内膜炎对比试验
2.2不同的用药次数对临床治疗的影响
复方黄藤素口服液临床治疗患子宫内膜炎母猪110头,其中用药1~3次后治愈26头,用药4~6次后治愈51头,用药7~9次后治愈28头,有5头没有治愈,有效率为95.5%。
2.3不同子宫内膜炎类型的临床治疗结果
在临床治疗的110头母猪中,共有五种子宫内膜炎(急性卡他性、急性纤维蛋白性、慢性脓性子宫内膜炎、慢性子宫炎、隐性子宫炎)的类型,经过复方黄藤素口服治疗后,它们的有效率如表5:
表5不同子宫内膜炎类型的临床治疗结果
3讨论
3..1复方黄藤素口服液治疗母猪子宫内膜炎对比试验结果显示复方黄藤素口服液对母猪子宫内膜炎的治愈效果明显高于连翘+益母草提取液,赤芍+益母草提取液,黄藤+益母草提取液,黄藤+连翘+益母草提取液,黄藤+赤芍+益母草提取液组。说明复方黄藤素口服液组方具有很好的协同作用。
3.2在本次临床试验的110头病例中,复方黄藤素口服液作为治疗母猪子宫内膜炎的药物,表现出了良好的疗效。在患病母猪中,其中大多数得到治愈或明显好转,有效率达到95.5%。其治疗母猪子宫内膜炎疾病,用药方法为每天用药1次。在临床治疗的过程当中,有的母猪只需用药1~3次即可痊愈,而有些母猪用药次数4~6次才表现出较好的疗效,其中用药4~6次的病例有效率最高,说明对于该复方黄藤素口服液,连续用药4~6次是最合适的。
3.3由表4可知,该中药口服液对急性卡他性、急性纤维蛋白性、慢性脓性子宫内膜炎的临床有效率达到100%,而对慢性子宫炎、隐性子宫炎的有效率只有89%和80%。一般情况下,母猪子宫内膜炎常在产后2周内发生,大多数为急性病例,如果患猪能得到即使治疗,则可避免炎症的扩散或转化为慢性炎症。因此子宫内膜炎疾病应该早发现、早治疗。
3.4该中药复方是在严格进行单味中药筛选的基础上,依据中药组方和子宫内膜炎疾病的治疗原则,进行药物的配伍,临床结果表明,该中药复方对母猪子宫内膜炎疾病表现出较好的疗效。
Claims (6)
1.一种治疗母猪子宫内膜炎的中药口服液,其特征在于,1000mL所述中药口服液由如下重量的生药制得:黄藤素300—400g,连翘100—300g,赤芍100—300g,益母草150—250g。
2.如权利要求1所述治疗母猪子宫内膜炎的中药口服液,其特征在于,1000mL所述中药口服液由如下重量的生药制得:黄藤素300—400g,连翘200—300g,赤芍200—300g,益母草200g。
3.如权利要求1或2所述治疗母猪子宫内膜炎的中药口服液,其特征在于,1000mL所述中药口服液中还含有如下组分:乙醇80—120mL,蔗糖80—120g,苯甲酸钠1.5—2.5g。
4.如权利要求3所述治疗母猪子宫内膜炎的中药口服液,其特征在于,1000mL所述中药口服液中还含有如下组分:体积百分比含量为95%的乙醇100mL,蔗糖100g,苯甲酸钠2g。
5.如权利要求3所述治疗母猪子宫内膜炎的中药口服液,其特征在于,所述中药口服液的制备方法如下:
(1)按所述比例准备生药和组分;
(2)提取黄藤素:取黄藤素饮片粉碎备用,取黄藤素干粉按料剂比为1:(4—6)加入体积百分比浓度为1.5—2.5%的H2SO4浸润8—12分钟,然后超声作用,25—35分钟,纱布过滤,然后用高速离心机进行离心得上清液,上清液调PH值到7.0后按每100mL上清液加入6—8gNaCl,搅拌使NaCl充分溶解,静置20—28小时后再离心,得沉淀即为粗碱,粗碱自然风干粉碎,然后再进行重结晶及可得到黄藤素提取物;所述重结晶过程是用体积百分比浓度为80%的酒精提取2—3次,提取液用HCl调PH值到7.0,冷却结晶;
(3)提取连翘:取连翘,粉碎成粗粉,加水煎煮2—3次,每次加水重量均为连翘粗粉重量的6—8倍,每次1—1.5小时,合并煎液,滤过,滤液于60℃以下减压浓缩至相对密度为1.1—1.2的浸膏,放冷,按浸膏重量加入3—5倍量乙醇,搅匀,静置1.5—2.5小时,沉淀,滤过,滤液减压回收乙醇,浓缩液喷雾干燥,即得;
(4)提取益母草:将益母草加水煎煮3次,加水重量分别为益母草重量的13—17倍1.5—2小时,10—12倍量1—1.5小时,9—10倍量0.5—1小时,滤过,合并滤液,浓缩,冷却,得益母草提取浓缩液体积,加入与益母草提取浓缩液体积等量的体积百分比浓度为95%的乙醇,搅匀,常温静置20—28小时,滤过,滤渣用体积百分比浓度为45%的乙醇洗涤,合并滤液与洗液,减压浓缩,浓缩液即得;所述倍量是加水重量与益母草重量的比值;
(5)提取赤芍:将赤芍加入7—9倍量体积百分比浓度为70﹪的乙醇,提取2—3次,每次浸取1—1.5小时,过滤,收集滤液,减压浓缩并回收乙醇,浓缩液即得;所述倍量是加水重量与赤芍重量的比值;
(6)将黄藤素、连翘、赤芍、益母草中草材的提取物混合、加入乙醇及水溶解后加入蔗糖、苯甲酸钠,过滤、灌封、灭菌。
6.如权利要求5所述治疗母猪子宫内膜炎的中药口服液,其特征在于,所述中药口服液的制备方法如下:
(1)按所述比例准备生药和组分;
(2)提取黄藤素:取黄藤素饮片粉碎备用,取黄藤素干粉按料剂比为1:5加入体积百分比浓度为2%的H2SO4浸润10分钟,然后超声作用,30分钟,4层纱布过滤,然后用高速离心机进行离心得上清液,上清液调PH值到7.0后按每100mL上清液加入7gNaCl,搅拌使NaCl充分溶解,静置24小时后再离心,得沉淀即为粗碱,粗碱自然风干粉碎,然后再进行重结晶及可得到黄藤素提取物;所述重结晶过程是用体积百分比浓度为80%的酒精提取3次,提取液用HCl调PH值到7.0,冷却结晶;
(3)提取连翘:取连翘,粉碎成粗粉,加水煎煮3次,加水重量均为连翘粗粉重量的7倍,每次1.5小时,合并煎液,滤过,滤液于60℃以下减压浓缩至相对密度为1.1—1.2的浸膏,放冷,按连翘提取浸膏量加入3-5倍量乙醇,搅匀,静置2小时,沉淀,滤过,滤液减压回收乙醇,浓缩液喷雾干燥,即得;
(4)提取益母草:将益母草加水煎煮3次,每次加水重量分别为益母草重量的13—17倍1.5—2小时,10—12倍量1—1.5小时,9—10倍量0.5—1小时,滤过,合并滤液,浓缩,冷却,得益母草提取浓缩液体积,加入与益母草提取浓缩液体积等量的体积百分比浓度为95%的乙醇,搅匀,常温静置24小时,滤过,滤渣用体积百分比浓度为45%的乙醇洗涤,合并滤液与洗液,减压浓缩,浓缩液即得;所述倍量是加水重量与益母草重量的比值;
(5)提取赤芍:按赤芍重量加入8倍量体积百分比浓度为70﹪的乙醇,提取3次,每次浸取1小时,过滤,收集滤液,减压浓缩并回收乙醇,浓缩液即得;所述倍量是加水重量与赤芍重量的比值;
(6)将黄藤素、连翘、赤芍、益母草中草材的提取物混合、加入乙醇及水溶解后加入蔗糖、苯甲酸钠,过滤、灌封、灭菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610030763.XA CN105641081A (zh) | 2016-01-18 | 2016-01-18 | 一种治疗母猪子宫内膜炎的中药口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610030763.XA CN105641081A (zh) | 2016-01-18 | 2016-01-18 | 一种治疗母猪子宫内膜炎的中药口服液 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105641081A true CN105641081A (zh) | 2016-06-08 |
Family
ID=56487428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610030763.XA Pending CN105641081A (zh) | 2016-01-18 | 2016-01-18 | 一种治疗母猪子宫内膜炎的中药口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105641081A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105963646A (zh) * | 2016-07-18 | 2016-09-28 | 安徽奥力欣生物科技有限公司 | 一种治疗母猪子宫内膜炎中药微生态制剂及其制备方法 |
CN106074731A (zh) * | 2016-06-27 | 2016-11-09 | 烟台海研制药有限公司 | 一种治疗母猪子宫内膜炎的中药灌注液 |
CN112772787A (zh) * | 2021-01-19 | 2021-05-11 | 六安恒佳生物科技有限公司 | 一种清除母猪子宫毒素并提高产活仔数添加剂 |
-
2016
- 2016-01-18 CN CN201610030763.XA patent/CN105641081A/zh active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106074731A (zh) * | 2016-06-27 | 2016-11-09 | 烟台海研制药有限公司 | 一种治疗母猪子宫内膜炎的中药灌注液 |
CN105963646A (zh) * | 2016-07-18 | 2016-09-28 | 安徽奥力欣生物科技有限公司 | 一种治疗母猪子宫内膜炎中药微生态制剂及其制备方法 |
CN112772787A (zh) * | 2021-01-19 | 2021-05-11 | 六安恒佳生物科技有限公司 | 一种清除母猪子宫毒素并提高产活仔数添加剂 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103721131B (zh) | 一种治疗妇女慢性盆腔炎的中药栓剂及其制备方法 | |
CN104288356B (zh) | 治疗奶牛乳房炎的中药灌注液及其制备方法 | |
CN105166545A (zh) | 一种牛配合饲料及其制备方法 | |
CN102552769A (zh) | 一种治疗阴道炎的药物及其制备方法 | |
CN105641081A (zh) | 一种治疗母猪子宫内膜炎的中药口服液 | |
CN104436142B (zh) | 一种治疗猪流行性腹泻的中药组合物 | |
CN100366630C (zh) | 一种治疗慢性咽炎、慢性扁桃体炎的中药有效部位山香园总黄酮的制备方法 | |
CN104208294B (zh) | 一种用于治疗仔猪黄白痢的中药组合物及其制备方法 | |
CN105617316A (zh) | 一种检验科用抑菌消毒液及制备方法 | |
CN103494927B (zh) | 一种用于治疗鸡呼吸道疾病的中药组合物及其制备方法 | |
CN111514231A (zh) | 一种麻杏宣肺中药组合物作为流感病毒治疗药物的应用 | |
CN105535391A (zh) | 一种治疗肺炎的药物组合物 | |
CN105497096A (zh) | 治疗肝腹水的药物组合物及其制备方法 | |
CN109432287B (zh) | 一种防治家禽气分热盛证的中药口服液及其制备方法 | |
CN105687315A (zh) | 防治奶牛乳房炎的中药灌注剂及其制备方法 | |
CN103071148B (zh) | 一种提高仔猪存活率的复方胸腺肽α1注射液及制备方法 | |
CN102114134A (zh) | 一种治疗牲畜及家禽疾病的中药组合物 | |
CN102772790B (zh) | 一种复方紫锥菊制剂及其制备方法和应用 | |
CN1772073B (zh) | 一种治疗咽喉口腔疾病的药物组合物与其制备工艺 | |
CN107308254A (zh) | 八正片及其制备方法 | |
CN103599437A (zh) | 一种治疗阴道炎的中药药液 | |
CN103720930B (zh) | 一种治疗奶牛乳腺炎的中药组合物 | |
CN103919895A (zh) | 一种调理肠胃、治疗便秘的中药酒 | |
CN103550360A (zh) | 一种复方白头翁颗粒剂及其制备方法 | |
CN103816265B (zh) | 一种用于治疗泄泻的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160608 |
|
RJ01 | Rejection of invention patent application after publication |